Propelled by a confluence of factors, brain-computer interface (BCI) technology is on the verge of entering a 'golden window period' for extensive commercialization, with 2026 projected to mark its inaugural year of widespread adoption. According to statistics from Securities Times · Data Treasure, the A-share market boasts fewer than 30 stocks associated with the BCI concept. Among these, some companies indirectly establish their presence by acquiring stakes in BCI enterprises, others collaborate with academic institutions on research and development endeavors, and a select few have independently developed BCI products. Insights from institutional research shed light on the progress of these concept stocks' strategic deployments. As of the market close on April 3, five concept stocks have garnered attention from over 100 institutions this year, namely Xiangyu Medical, Aipen Medical, ZKTeco, Biotest, and 37 Interactive Entertainment.